Rehan Hussain, MD
Ophthalmology · Elgin, ILNPI 1922340066
Payments from drug & device makers
Across 132 payments — averaging $245.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$16K
- Regeneron$6K
- Apellis Pharmaceuticals, Inc.$3K
- Eyepoint US, Inc.$2K
- AbbVie$1K
- Astellas Pharma US Inc$770
- plus $3K from 15 others
What the payments were for
- Consulting fees$9,76130%
- Speaking & faculty fees$12,20038%
- Travel & lodging$2,6068%
- Food & beverage$7,87924%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 37 | $15,682 |
| Regeneron | 8 | $6,081 |
| Apellis Pharmaceuticals, Inc. | 10 | $3,134 |
| Eyepoint US, Inc. | 10 | $2,371 |
| AbbVie(2 entities) | 13 | $1,497 |
| Astellas Pharma US Inc | 10 | $770 |
| Novartis | 8 | $736 |
| Regeneron Healthcare Solutions, Inc. | 11 | $600 |
| Genentech USA, Inc. | 6 | $244 |
| Alcon | 2 | $191 |
| Harrow Eye, LLC | 2 | $161 |
| Bausch & Lomb Americas Inc. | 2 | $138 |
| Sight Sciences, Inc. | 1 | $138 |
| Biotissue Holdings Inc. | 1 | $129 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $127 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $125 |
| Astellas Pharma Global Development | 1 | $100 |
| Ocular Therapeutix, Inc. | 2 | $81 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| ANI Pharmaceuticals, Inc. | 2 | $51 |
| Mallinckrodt Hospital Products Inc. | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$14,753
- EYLEA HD$4,825
- Syfovre$2,976
- EYP-1901$1,727
- OZURDEX$1,118
- Izervay$488
- EYLEA$469
- YUTIQ$258
- Lucentis$151
- OMNI(R) SURGICAL SYSTEM (US)$138
- Prokera$129
- AmnioGraft$129
- Tecnis Symfony IOL$125
- IHEEZO$125
- BEOVU$124
- DUREZOL$120
- VYZULTA$111
- LOTEMAX SM$111
- PROLENSA$111
- DEXYCU$106
How this compares
$32,463 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 171 | $6,725 |
| Brimonidine Tartrate | 59 | $2,985 |
| Ketorolac Tromethamine | 109 | $1,789 |
| Timolol Maleate | 36 | $948 |
| Atropine Sulfate | 28 | $730 |
| Mycophenolate Mofetil | 11 | $679 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 57 | $667 |
| Latanoprost | 61 | $607 |
| MoxifloxacinMoxifloxacin Hcl | 23 | $465 |
| Eplerenone | 11 | $319 |
| Dorzolamide Hcl | 13 | $142 |
| ErythromycinErythromycin Base | 14 | $114 |
| Prednisone | 11 | $27 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Elgin
- Veeral ShethOak Forest$14.8M
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.9M
- Manjot GillChicago$1.4M
- Mitchell JacksonLake Villa$1.4M
- Ramanath BhandariSpringfield$1.2M
- Kathleen MornoNorth Riverside$1.2M
- Amani FawziChicago$864K
- Navaneet Chailert BorisuthRock Island$737K
- David LubeckHomewood$709K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.